Teva Zecuity's Safety: Burns Go From Non-Issue In Label To Product Puller
This article was originally published in The Pink Sheet Daily
Executive Summary
Fate of migraine patch remains uncertian after 'large number' of patients suffer burns and scars; adverse event was issue during review of transdermal sumatriptan product, but didn't even make it into labeling; nine months later the problems have forced Teva to suspend marketing.